Results from the HELIOS Trial: A Phase 2 Open-Label Study Evaluating an Oral, Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol in Wolfram Syndrome

Fumihiko Urano¹, Bess Marshall², Stacy Hurst¹, Amy Viehoever³, Saumel Ahmadi³, Tamara Hershey⁴, Gregory Van Stavern,⁵ Paulina Cruz Bravo¹, Jennifer Powers Carson¹, Nathalie Erpelding⁶, Kelsi Cottrell⁶, Mathias Leinders⁶, John Pesko,⁶ Lahar Mehta⁶

¹Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis, Missouri, USA; ²Departments of Pediatrics and Cell Biology, Division of Endocrinology and Diabetes, Washington University School of Medicine, St. Louis, Missouri, USA; ⁴Departments of Psychiatry and Radiology, Washington University School of Medicine, St. Louis, Missouri, USA; ⁴Departments of Psychiatry and Radiology, Washington University School of Medicine, St. Louis, Missouri, USA; ⁴Departments of Psychiatry and Radiology, Washington University School of Medicine, St. Louis, Missouri, USA; ⁴Departments of Psychiatry and Radiology, Washington University School of Medicine, St. Louis, Missouri, USA; ⁴Departments of Psychiatry and Radiology, Washington University School of Medicine, St. Louis, Missouri, USA; ⁴Departments of Psychiatry and Radiology, Washington University School of Medicine, St. Louis, Missouri, USA; ⁴Departments of Psychiatry and Radiology, Washington University School of Medicine, St. Louis, Missouri, USA; ⁴Departments of Psychiatry and Radiology, Washington University School of Medicine, St. Louis, Missouri, USA; ⁴Departments of Psychiatry and Radiology, Washington University School of Medicine, St. Louis, Missouri, USA; ⁴Departments of Psychiatry and Radiology, Washington University School of Medicine, St. Louis, Missouri, USA; ⁴Departments of Psychiatry and Radiology, Washington University School of Medicine, St. Louis, Missouri, USA; ⁴Departments of Psychiatry and Radiology, Washington University School of Medicine, St. Louis, Missouri, USA; ⁴Departments, St. Louis, Missouri, USA; ⁴Department, St. Louis, Missouri, St. Louis, Medicine, St. Louis, Missouri, USA; ⁵Department of Ophthalmology & Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, USA; ⁶Amylyx Pharmaceuticals, Inc., Cambridge, Massachusetts, USA

BACKGROUND

HF

- Wolfram syndrome (WS) is a rare, fatal, progressive monogenic disorder characterized by juvenile-onset diabetes mellitus, optic nerve atrophy, diabetes insipidus, sensorineural hearing loss, and neurodegeneration¹⁻⁵
- PB&TURSO is an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol hypothesized to simultaneously target endoplasmic reticulum (ER) stress and mitochondrial dysfunction⁶⁻⁷, two pathways critical to the development of Wolfram syndrome^{1,8,9}
 - PB&TURSO has demonstrated pre-clinical efficacy in patient-derived cell and mouse WS models¹⁰
- The phase 2, open-label HELIOS trial is evaluating the safety/tolerability of PB&TURSO and its effects on

RESULTS

- The main analysis performed includes Week 24 data for all 12 participants (the Intent-to-Treat [ITT] population) and for the 11 participants with genetically confirmed Wolfram syndrome (the Per Protocol population)
 - Upon genetic review, one participant was determined not to meet inclusion/exclusion criteria; this participant had a pathogenic autosomal recessive mutation on one allele and a variant of uncertain significance on the other
- Treatment with PB&TURSO showed overall stabilization or improvement relative to baseline on multiple outcomes across organ systems typically affected in Wolfram syndrome¹, including endocrine function (Figure 1), ophthalmologic function (Figure 2), and overall symptom burden (Figures 3 and 4)
- PB&TURSO was generally well tolerated with no serious adverse events and all treatment-emergent adverse events (TEAEs) graded mild or moderate
 - Diarrhea was the most common TEAE (50% in ITT); all cases were of mild severity
 - Most TEAEs did not lead to modification or interruption of PB&TURSO dosing and none led to drug discontinuation

FIGURE 1. Improved Pancreatic Function, Beta Cell Responsiveness, and Glycemic Control

endocrinologic, neurologic, and ophthalmologic function in Wolfram syndrome

STUDY DESIGN


Key Trial

Entry Criteria

Trial Efficacy

Endpoints






Key Diabetic Outcomes in Per Protocol Population

Poster

#94




- Aged ≥17 years
- Definite diagnosis of Wolfram syndrome^a
- Stimulated C-peptide level of ≥0.2 ng/mL at Screening
- Insulin-dependent diabetes mellitus due to Wolfram syndrome
- No current GLP-1 agonist use

Primary Efficacy Endpoints

• Change from baseline in **C-peptide** (ΔC-peptide, area under the curve [AUC] C-peptide) at Week 24 using 240-minute mixed meal tolerance tests (MMTTs) C-peptide is co-secreted in a 1:1 ratio with insulin and is a measure of endogenous insulin secretion and pancreatic beta

FIGURE 2. Trend Toward Visual Acuity Stabilization at Week 24 Compared to Baseline



- 8 of 11 Per Protocol participants demonstrated improved or stable visual acuity in their best eye from baseline to the latest available timepoint
 - Of remaining participants:
 - 2 stable in one eye

1 worsened

cell function

Key Secondary Efficacy Endpoints

- Change from baseline in **best-corrected visual acuity** on the LogMAR scale using the Snellen chart
- Change from baseline in overall time in target glucose range (70–180 mg/dL) by continuous glucose monitoring (CGM)
- Change from baseline in **hemoglobin A1c (HbA1c)**

Select Exploratory Endpoints

- Clinician-Reported Global Impression of Change^b
- Patient-Reported Global Impression of Change^b
- Change from baseline in Most Bothersome Symptom^b

^aDocumented functionally relevant recessive mutations on both alleles of the WFS1 gene based on historical test results (if available) or from a qualified laboratory at Screening ^bAsked to rate participant's change in symptom status since study start using a 7-point scale from 'Very Much Worse' to 'Very Much Improved'

CONCLUSIONS

- While the natural history of Wolfram syndrome would suggest pancreatic β -cell function, glycemic control, visual function, and overall symptom burden should worsen over time^{11,12}, treatment with PB&TURSO instead showed overall stabilization or improvement relative to baseline
- Analyses once all 12 participants have completed Week 48 assessments will provide additional insight
- Results will inform planned Phase 3 program

Positive change relative to expected disease progression¹²

FIGURE 3. Reduced Overall Symptom Burden at Week 24 by Clinician and Patient Report





FIGURE 4. Stabilization or Improvement in Most Bothersome Symptom at Week 24



PB&TURSO is an investigational drug for Wolfram syndrome and has not been approved for use by any health authority (eg, the FDA and EMA).

Acknowledgments

The authors would like to thank the people living with Wolfram syndrome, their caregivers and family members, and advocates for providing feedback and advice on the study design. This study is sponsored by Amylyx Pharmaceuticals, Inc.

Disclosures

NE, KC, ML, JP, and LM are or were full-time employees of Amylyx who may have had stock option/ownership in Amylyx Pharmaceuticals, Inc. at the time of the study.



References

1. Urano F. Diabetes. 2014;63(3):844-846. 2. Pallotta MT, et al. J Transl Med. 2019;17:238. 3. Lee E, et al. Front Genet. 2023;14:1198171. 4. Leslie M. Science. 2021;371(6530):663-665. 5. Matsunage et al. Plos One. 2014;9(9):106906. 6. Paganoni S, et al. N Engl J Med. 2020;383(10):919-930. 7. Paganoni S, et al. Supplemental appendix. N Engl J Med. 2020;383(10):919-930. Accessed October 2, 2023. https://www.nejm.org/doi/full/10.1056/nejmoa1916945. 8. Mishra R, et al. Ther Adv Rare Dis. 2021:2:26330040211039518. 9. Sarmara A, et al. Orphanet J Rare Dis. 2019; 14(1):279. 10. Kitamura RA, et al. JCI Insight. 2022;7(18):e156549. 11. Ray MK, et al. Pediatr Diabetes. 2022;23(2):212-218. 12. O'Bryhim BE,et al. Am J Ophthalmol. 2022;243:10-18. 13. Washburn RL, et al. Biomedicines. 2021;9(3):270. 14. Stankute I, et al. Diabetes Res Clin Pract. 2021; 178:108938. doi 10.1016/j.diabres.2021.108938. Epub 2021 Jul 1. PMID: 34217772. **15.** Kondo M, et al. *Diabetologia*. 2018;61(10);2189-2201.

Presented at the 53rd Child Neurology Society Annual Meeting; Nov. 11-14, 2024; San Diego, CA

